VIALE, GIUSEPPE

VIALE, GIUSEPPE  

Dipartimento di Oncologia ed Emato-Oncologia  

Mostra records
Risultati 1 - 20 di 600 (tempo di esecuzione: 0.005 secondi).
Titolo Data di pubblicazione Autori Tipo File Abstract
Advances in Early Breast Cancer Risk Profiling: From Histopathology to Molecular Technologies 2023 Carlo PesciaElena Guerini-RoccoGiuseppe VialeNicola Fusco Article (author) -
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread 2023 Carmen CriscitielloChiara CortiFrancesco Di MecoGiuseppe VialeGiuseppe Curigliano + Article (author) -
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC) 2023 Vingiani A.Viale G.Pruneri G. + Article (author) -
TMEM123 a key player in immune surveillance of colorectal cancer 2023 Pesce, ElisaOliveto, StefaniaManara, CristinaBevilacqua, ValeriaDe Camilli, ElisaCassinotti, ElisaBaldari, LudovicaViale, GiuseppeBiffo, StefanoAbrignani, Sergio + Article (author) -
Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer: A Randomized Clinical Trial 2023 Veronesi, PaoloViale, GiuseppeLazzeroni, MatteoJohansson, Harriet + Article (author) -
The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients 2022 Veronesi, PaoloViale, Giuseppe + Article (author) -
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review 2022 Curigliano, GiuseppeViale, Giuseppe + Article (author) -
Breast Cancer during Pregnancy as a Special Type of Early-Onset Breast Cancer: Analysis of the Tumor Immune Microenvironment and Risk Profiles 2022 Sajjadi, ElhamVenetis, KonstantinosBlundo, ConcettaFerrero, StefanoVeronesi, PaoloViale, GiuseppeFusco, NicolaGuerini-Rocco, Elena + Article (author) -
Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis 2022 Rocco E. G.Viale G. + Article (author) -
Sex and cancer immunotherapy: Current understanding and challenges 2022 Minucci, SaverioViale, GiuseppeConforti, Fabio + Article (author) -
Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status 2022 Viale, Giuseppe + Article (author) -
Advances and controversies in management of breast ductal carcinoma in situ (DCIS) 2022 Viale, GiuseppeCurigliano, GiuseppeVeronesi, Paolo + Article (author) -
Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials: A Systematic Review and Meta-analysis 2022 Viale, Giuseppe + Article (author) -
Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130 2022 Viale, Giuseppe + Article (author) -
HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer 2022 Venetis K.Crimini E.Sajjadi E.Corti C.Guerini-Rocco E.Viale G.Curigliano G.Criscitiello C.Fusco N. Article (author) -
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer 2022 Viale G. + Article (author) -
Pathology after neoadjuvant treatment – How to assess residual disease 2022 Viale G.Fusco N. Article (author) -
LINE1 are spliced in non-canonical transcript variants to regulate T cell quiescence and exhaustion 2022 Marasca F.Sinha S.Ranzani V.Paraboschi E. M.Burattin F. V.Notarbartolo S.Sartore-Bianchi A.Siena S.Montini G.Viale G.Harari S.Biffo S.Abrignani S.Bodega B. + Article (author) -
CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one- carbon metabolism in breast cancer 2022 Filippone, M. G.Bonfanti, R.Tucci, F. A.Montani, F.Freddi, S.Taglialatela, A.Romanenghi, M.Vago, G.Viale, G.Di Fiore, P. P.Minucci, S.Veronesi, P.Pece, S. + Article (author) -
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study 2022 Viale, G + Article (author) -